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NMI inhibits cancer stem cell traits by downregulating
hTERT in breast cancer
Xu Feng1,2,5, Xiangdong Xu3,5, Xiangsheng Xiao2,5, Kun Zou1,5, Wendan Yu1, Jiali Wu2, Ranran Tang1, Yue Gao1, Jiaojiao Hao1,
Xinrui Zhao1, Yina Liao1, Yiming Chen1, Wenlin Huang2,4, Wei Guo*,1, Lan Kang*,1 and Wuguo Deng*,2,4
N-myc and STAT interactor (NMI) has been proved to bind to different transcription factors to regulate a variety of signaling
mechanisms including DNA damage, cell cycle and epithelial–mesenchymal transition. However, the role of NMI in the regulation of
cancer stem cells (CSCs) remains poorly understood. In this study, we investigated the regulation of NMI on CSCs traits in breast
cancer and uncovered the underlying molecular mechanisms. We found that NMI was lowly expressed in breast cancer stem cells
(BCSCs)-enriched populations. Knockdown of NMI promoted CSCs traits while its overexpression inhibited CSCs traits, including
the expression of CSC-related markers, the number of CD44+CD24− cell populations and the ability of mammospheres formation.
We also found that NMI-mediated regulation of BCSCs traits was at least partially realized through the modulation of hTERT
signaling. NMI knockdown upregulated hTERT expression while its overexpression downregulated hTERT in breast cancer cells,
and the changes in CSCs traits and cell invasion ability mediated by NMI were rescued by hTERT. The in vivo study also validated
that NMI knockdown promoted breast cancer growth by upregulating hTERT signaling in a mouse model. Moreover, further
analyses for the clinical samples demonstrated that NMI expression was negatively correlated with hTERT expression and the low
NMI/high hTERT expression was associated with the worse status of clinical TNM stages in breast cancer patients. Furthermore,
we demonstrated that the interaction of YY1 protein with NMI and its involvement in NMI-mediated transcriptional regulation of
hTERT in breast cancer cells. Collectively, our results provide new insights into understanding the regulatory mechanism of CSCs
and suggest that the NMI-YY1-hTERT signaling axis may be a potential therapeutic target for breast cancers.
Cell Death and Disease (2017) 8, e2783; doi:10.1038/cddis.2017.200; published online 11 May 2017
Breast cancer is one of the leading mortal causes from cancer
among women worldwide.1,2 Surgery, radiotherapy, che-
motherapy and hormone therapy are still the main and
common therapeutic approaches to treat breast cancer.3
However, some chances to recurrence and metastasis limited
their efficiencies. Cancer stem cells (CSCs), including breast
cancer stem cells (BCSCs), have been shown to play
important roles in cancer’s recurrence and metastasis.4–6
BCSCs are also relatively resistant to chemotherapy and
radiotherapy compared with their non-tumorigenic progeny.7–9
Therefore, it is necessary to discover and identify the novel
and specific molecular targets and their related signaling
pathways to inhibit the mammary stem/progenitor cell
population and suppress carcinogenesis and tumor
metastasis.
NMI is a protein involved in the transcriptional regulation of
genes. It lacks an intrinsic transcriptional activation domain,
but can act as a co-activator protein to recruit a group of
sequence-specific transcription factors, such as c-myc,
N-myc, Sox-10 and STATs.10–12 NMI can be induced by IFN
and mediates a variety of signaling mechanisms. Recent
studies have shown that NMI can suppress tumor invasion and
metastasis by inhibiting the acetylation of p65 through NF-κB
pathway.13 Loss of NMI can enhance the invasive ability of
breast cancer by aberrant activation of TGF-β/SMAD
signaling.14 NMI can also suppress tumor growth by
inhibiting the Wnt/b-catenin signaling via upregulation of
DKK1.15 However, whether NMI has anti-cancer role through
regulating the growth of cancer stem cells (CSCs) has not
been reported.
Human telomerase reverse transcriptase (hTERT) is a
catalytic component of telomerase, which can elongate
telomeric DNA.16 It is expressed in both bulk cancer cells and
CSCs.17 Recent studies have shown that hTERTexpression is
closely correlated with a clinical aggressiveness and poor
prognosis in many human malignancies.18–21 In addition,
hTERT has been shown to stimulate EMT and induce
stemness in human gastric cancer cells, thereby promote
cancer metastasis and recurrence.22 The hTERT inhibitor,
imetelstat, has been shown to target the CSCs population in a
number of tumor types, suggesting CSCs are sensitive to
telomerase inhibition.23,24 These findings make telomerase
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inhibition a striking strategy for potential cancer therapeutics
by targeting CSCs.
In this study, we tried to uncover the potential function and
molecular mechanisms of NMI in breast cancer, especially in
BCSCs.We not only found its low expression in BCSC-enriched
populations, its regulation on CSCs traits, but also found that
NMI-mediated regulation of BCSCs traits was partially realized
through the modulation of hTERT signaling. NMI negatively
regulated hTERTexpression in breast cancer cells, and hTERT
silencing or overexpression reversed the NMI silencing or
overexpression-mediated changes in BCSCs traits in vitro and
in vivo. Moreover, the involvement of YY1 protein in NMI-
mediated transcriptional regulation of hTERT in breast cancer
was identified and confirmed. Combined with the analysis from
the clinical samples demonstrating that NMI expression was
inversely correlated with hTERT and the low NMI/high hTERT
expression was associated with theworse status of clinical TNM
stages in breast cancer patients, our findings may provide new
insights into identifying the unknown central proteins involved in
regulating BCSCs traits, understanding the underlying regula-
tory mechanism of such regulation and exploring new ther-
apeutic targets for breast cancer treatment.
Results
NMI is downregulated in BCSCs-enriched populations.
To assess the role of NMI in BCSCs, we first determined the
expression levels of NMI and CSC-related markers in
mammospheres. The breast cancer cells were cultured in a
suspension culture condition to enrich mammospheres. In
the suspension culture condition, the CD44+CD24− BCSCs
populations were enriched (Figure 1a), and the expression of
NMI and CSC-related markers in mammospheres were
analyzed at protein and mRNA levels by western blot
(Figures 1b and d) and qRT-PCR (Figure 1c), respectively.
The results showed that the NMI was downregulated in
mammospheres at both protein (Figures 1b and d) and
mRNA levels (Figure 1c) as compared with the monolayer
adherent culture. However, the levels of the CSC-related
markers (NANOG, OCT4 and SOX2) were upregulated in
mammospheres (Figures 1c and d). When the mammo-
spheres were dissociated and cultured in the differentiation
medium (RMPI1640 with 10% FBS), the level of NMI was
increased but the CSC-related markers were decreased
(Figure 1d). Moreover, we also analyzed the expression level
of NMI using genome mRNA expression profiling data
(GSE7515, GSE15192) from GEO database. As shown in
Figures 1e and f, the expression of NMI was downregulated
in breast cancer mammospheres compared with primary
breast cancer (Figure 1e) and NMI was also downregulated in
the CD44+CD24− cells compared with the CD44−CD24+ cell
populations (Figure 1f). These results indicate that NMI is
downregulated in the BCSCs-enriched populations.
NMI knockdown promotes CSCs properties of breast
cancer cells. To explore the function of NMI in BCSCs, we
first analyzed the expression level of NMI in different human
breast cancer cell lines by western blot and found that NMI
displayed comparatively high expression in MCF7 and T47D
while low expression in MDA-MB-231 (data not shown). So
we chose MCF7 and T47D to knockdown NMI and MDA-
MB-231 to overexpress NMI. We knocked down NMI and
detected its influence on the properties of BCSCs. It showed
that knockdown of NMI upregulated the expression of the
CSC-related markers at both protein and mRNA levels
(Figures 2a and b). Moreover, NMI knockdown also sig-
nificantly increased the mammosphere number and size in
both MCF7 cells and T47D cells (Figures 2c and d). Similarly,
the same phenomenon was observed in the CD44+CD24−
proportion (Figures 2e and f). Recent evidence has shown
that the ABC family of transporters is associated with
CSCs.25–28 Thus, we also detected their expression when
NMI was knocked down. The results showed that knockdown
of NMI led to the increased expression of ABC transporter
genes such as ABCG2 and ABCB1 (Supplementary
Figure 1). These results demonstrate that NMI acts as a
potential repressor to inhibit CSCs properties of breast
cancer cells.
NMI overexpression inhibits CSCs properties of breast
cancer cells. Next, we analyzed the function of NMI on the
properties of BCSCs by overexpressing it in MDA-MB-231
cells. Compared with the cells expressing the empty vector,
the CSC-related markers of cells with NMI overexpression
were decreased at both protein and mRNA level (Figures 3a
and b). Moreover, NMI overexpression also significantly
inhibited the mammosphere number and size in MDA-
MB-231 as compared with the control group (Figures 3c
and d). Similarly, the same phenomenon was observed in the
CD44+CD24− proportion (Figures 3e and f). Furthermore, the
overexpression of NMI also significantly inhibited breast
tumorigenicity in mouse model bearing xenografts of
MDA-MB-231 cells (Figure 3g). H&E staining detection and
bioluminescent imaging both showed that when
MDA-MB-231 cells with NMI overexpression were injected
into tail vein of mice, the lung metastasis ability was inhibited
(Figures 3h and i). Hence, NMI overexpression significantly
impaired CSCs expansion and tumorigenicity of breast
cancer cells.
NMI inhibits BCSCs traits by downregulating hTERT
expression. NMI has been reported to regulate hTERT
promoter activity.29 Based on the key role played by hTERT in
CSCs,17,30–32 we therefore hypothesized that hTERT might
be involved in the regulation of CSCs traits mediated by NMI.
To verify this, we first detected the effect of NMI on the
promoter activity of hTERT. The results showed that NMI
knockdown markedly upregulated the expression of lucifer-
ase driven by the hTERT promoter (Figure 4a). Additionally,
NMI knockdown also upregulated the expression of hTERT
protein, while its overexpression downregulated the hTERT
protein levels in breast cancer cells (Figure 4b). Furthermore,
we found that the expression changes of the CSC-related
markers caused by NMI knockdown were rescued by hTERT
knockdown, and the expression changes caused by NMI
overexpression were also rescued by hTERT overexpression
(Figure 4c). Similarly, knockdown of hTERT significantly
impaired the improved CD44+CD24− population ratio caused
by NMI knockdown, while its overexpression reversed NMI
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overexpression-mediated decrease of CD44+CD24− popula-
tion ratio (Figure 4d). The enhanced formation ability both in
number and size of mammospheres caused by NMI knock-
down could be attenuated again by hTERT knockdown, and
the NMI-mediated decrease of mammosphere number and
size could be promoted again by the overexpressed hTERT
(Figures 4e and f). Together, these results suggest that NMI
inhibits cancer stem-like cell traits by downregulating hTERT
signaling in breast cancer.
NMI suppresses EMT in breast cancer cell lines and
tumorigenicity in mouse model with xenografts of human
breast cancer by downregulating hTERT. Recent evi-
dences have shown that EMT factors are associated with
stemness in cancer cells, suggesting the existence of a link
between EMT and CSCs.33,34 We hereby tested the effect of
the NMI/hTERT signaling on the metastasis-related
properties, and found that NMI knockdown upregulated the
expression of EMT-related proteins, while NMI overexpres-
sion downregulated the EMT-related proteins in breast cancer
cells (Figure 5a). Moreover, consistent with the results ahead,
hTERT silencing or overexpression reversed NMI-mediated
expression changes of EMT-related proteins (Figure 5a).
Similarly, NMI overexpression-mediated inhibition on cell
invasion ability was also rescued by hTERT overexpression
(Figures 5b and c). Immumofluorescence assay was further
used to monitor the expression of vimentin, a metastasis-
related marker, and the images indicated that NMI-mediated
regulation of vimentin expression was rescued by the
hTERT (Figure 5d). All the results collectively demonstrated
NMI’s regulation on EMT in breast cancer cells by
targeting hTERT.
We next validated the NMI-mediated regulation of tumor
growth via the hTERT signaling in a human breast cancer
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Figure 1 NMI is lowly expressed in breast cancer stem cell-enriched populations. (a) The MCF7 and T47D cells were cultured in mammosphere culture condition to enrich
BCSCs. The CD44+CD24− cells population, which represented for BCSCs in mammospheres were analyzed by FACS. The monolayer cells in the normal culture condition were
used as the control. (b) The NMI expression level was detected by western blot and quantitatively expressing values were analyzed in mammospheres compared with monolayer
cells. (c), The mRNA expression of NMI and cancer stem-like cell related markers Nanog Oct4 and Sox2 in monolayer and mammospheres were detected by qRT-PCR. (d), The
protein expression of NMI and the CSC-related markers Nanog Oct4 and Sox2 in monolayer, mammospheres and redifferentiated sphere-forming cells were detected by Western
blot analysis. (e), The NMI mRNA levels in primary breast patient tissue and cancer spheroids were analyzed using genome mRNA expression profiling data (GSE7515) from
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mousemodel in vivo. TheMCF7 cells with different expression
of NMI and hTERT were subcutaneously injected into nude
mice. As shown in Figures 5e and f, knockdown of NMI
significantly promoted tumor growth. However, inhibition of
hTERT expression by hTERT shRNA effectively rescued the
in vivo tumor progression enhanced by NMI knockdown.
Notably, the mice with simultaneous knockdown of NMI and
hTERT displayed a decreased tumor-initiating ability com-
pared with the control mice without any gene knockdown. Two
mice in this group even failed to form tumors, so only 3 tumors
were shown in shNMI/shhTERT group. Moreover, the immu-
nohistochemical analyses for the tumor tissues of mice
revealed that NMI knockdown promoted the expression of
hTERT and Ki67 in vivo, and such promotion was similarly
reversed by hTERT knockdown (Figures 5g and h). Taken
together, these data confirmed that the NMI-mediated regula-
tion of tumor growth was realized through the modulation of
hTERT signaling in breast cancer.
YY1 interacts with NMI to mediate the downregulation of
hTERT. To determine whether the downregulation of hTERT
expression mediated by NMI was realized by cooperating
with some other transcriptional factors similarly binding to
hTERT promoter, we used co-immunoprecipitation to pull
down the potential proteins which interact with NMI protein.
Mass spectrometry (MS) analysis identified 98 proteins in the
cell nuclear protein extracts specifically interacting with NMI,
but not with IgG (Figure 6a). We also predicted multiple
potential transcription factor binding sites in the hTERT
promoter region (+40 to −902) by transcription factor
prediction software,35 and 250 proteins were identified with
the potential of binding to hTERT promoter. Among all these
proteins, YY1 was discovered as a new candidate which
could not only bind to the hTERT promoter but also interact
with the NMI protein (Figure 6a). The mass spectra of YY1
and its predicted binding site on hTERT promoter was
respectively shown in Figures 6b and c. YY1 is a well-known
transcription factor for its dual roles in regulating gene
expression, as an activator or a repressor, depending upon
the context in which YY1 binds to.36–40 Next, we analyzed the
subcellular localization of YY1 by immunofluorescent imaging
and found that YY1 mainly localized in cell nucleus
(Figure 6d), which was consistent with the localization of
NMI in cell nucleus (Supplementary Figure 2).
Co-immunoprecipitation assay also confirmed the interaction
between of NMI and YY1 in different breast cancer cells
(Figure 6e). To further verify that YY1 binds to the hTERT
promoter specifically in breast cancer, we also performed
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chromatin immunoprecipitation assay to detect the binding
ability of YY1 to the endogenous hTERT promoter. As we
expected, more chromatin hTERT promoter DNA were
amplified with YY1 antibody than IgG itself (Figure 6f). As
YY1 binding site (CATCATGGCCCC) in hTERT promoter
region was predicted, we made a mutation within the site
(Figure 6g). To identify whether the mutated site could
influence hTERT promoter-driven luciferase activity, we
co-transfected MCF7 cells with NMI-specific shRNAs or its
overexpressing plasmids and pGL4-hTERT promoter lucifer-
ase plasmids (WT or Mut), and then analyzed the activity of
luciferase reporter. The results showed that when YY1
binding site was mutated, the NMI-mediated downregulation
of hTERT promoter-driven luciferase expression was blocked
and the upregulation of hTERT promoter-driven luciferase
expression caused by NMI knockdown was also attenuated
(Figure 6h). In agreement with this, when YY1 was knocked
down, the NMI silencing-mediated upregulation of hTERT
promoter-driven luciferase expression showed no difference
with control group (Figure 6i). These data together suggest
that NMI interacts with YY1 to mediate the downregulation of
hTERT transcription in breast cancer.
NMI inversely correlates with hTERT in breast cancer
samples. Next, we studied the clinical significance of NMI-
hTERT axis in patients with breast cancer. We first analyzed
NMI level in paired human normal breast tissue and
corresponding breast tumor tissue using GEO database
(GSE70951). The decreased expression of NMI in tumor
tissue compared with normal tissue was shown (Figure 7a).
To investigate the correlation of NMI and hTERT, we analyzed
the data of stroma normal breast samples from GEO
database (GSE8977). It was shown that NMI expression
was inversely correlated with hTERT expression (Figure 7b).
We further assessed the expression of NMI and hTERT in
breast carcinomas from 138 cases by immunohistochemical
staining (Figure 7c). We also found the inverse correlation
between NMI and hTERT expression in these tumor tissue
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samples (Figures 7d and e). Moreover, the high NMI
expression but low hTERT expression was shown to be
significantly correlated with the better status of clinical TNM
stages, while the low NMI expression but high hTERT
expression predicted the worse status of clinical TNM stages
in breast cancer patients (Figures 7f and g). Overall, these data
demonstrated again the inverse regulation of hTERT expres-
sion by NMI and their prognostic significance in breast cancer.
Discussion
Recent studies have demonstrated that NMI is associated with
DNA damage, cell cycle control and epithelial–mesenchymal
transition (EMT). Previous studies showed that loss of NMI in
breast cancer progression could be one of the driving factors
that enhance invasive ability of breast cancer by aberrant
activation of TGF-β/SMAD signaling. Our experiment also
verified NMI’s influence on the invasion ability in breast cancer
and found another pathway involved. However, the functions
of NMI and its underlying molecular mechanisms as a tumor
suppressor in breast cancer stem cells (BCSCs) remain
unclear. In our study, we have revealed the function of NMI in
weakening CSCs traits in BCSCs and illustrated the under-
lyingmolecular mechanisms of such function. NMI knockdown
promotes CSCs expansion and tumorigenicity of breast
cancer cells, while NMI overexpression inhibits CSCs proper-
ties. Moreover, we have shown that NMI suppresses hTERT
expression, thereby inhibiting cancer stem-like cell traits in
breast cancer in vitro and in vivo. Especially in the lung
metastasis model of nude mouse, NMI overexpression
significantly inhibits lung metastasis ability of breast cancer
cells, and furthermore, the limiting dilution tumor formation
experiments indicated only the mouse injected with the
highest concentration of breast cancer cells with NMI
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overexpression formed tumors,fully demonstrating the
decreased stemness-like capacity in breast cancer cells with
NMI overexpression. Furthermore, YY1 was identified to
functionalize as the synergistic effector of NMI to co-regulate
hTERT transcription. To the best of our knowledge, it might be
the first time to report that NMI targets hTERT via cooperation
with YY1 to inhibit cancer stem-like cell traits and tumor growth
in breast cancer. All the data might serve as a basis for
discovering and identifying the novel therapeutic targets for
breast cancers.
Cancer stem cells possess the capacity to both self-renew
and differentiate.41,42 Telomerase is critical for the integrity of
stem cell compartments. In cancer stem cells, telomerase is
more efficient at telomere maintenance rather than being
reactivated. Thus, a better understanding of these molecular
events will help refine approaches to targeting telomerase in
cancer stem cells. As the core component of telomerase,
hTERT can promote cancer metastasis and recurrence, and is
closely correlated with aggressiveness and poor prognosis of
many different human carcinomas. The direct regulation of
hTERT on BCSCs traits was not represented in our study,
however, its transcription and expression was found to be
strictly controlled by NMI in breast cancer cells. Previous
studies showed that the complex of BRCA1, c-Myc and NMI
impaired induction of hTERT promoter activity mediated by
c-Myc. In this study, we identified the influence of the NMI-
hTERT axis on BCSCs, and also revealed the involvement of
YY1 in the regulation of hTERT expression mediated by NMI.
Not only that, hTERT knockdown or overexpression signifi-
cantly reversed NMI knockdown or overexpression-mediated
promotion or suppression in BCSCs stemness and tumor
development, fully clarifying hTERT functionalized as the key
downstream target molecule in mediating NMI’s tumor-
suppressing effect in breast cancer progression, and also
indicating the indispensable role of hTERT in the maintenance
of BCSCs traits. NMI/hTERT signaling inhibition may be a
striking target for potential CSCs therapeutics in breast cancer.
Here, we show that NMI knockdown notably upregulated
hTERT promoter-driven luciferase expression and thereby
upregulated hTERT expression, implicating the reverse
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transcriptional regulation of hTERT by NMI. Given the fact that
NMI acts as a common transcriptional co-activator, and NMI
lacks DNA-binding domains and is involved in the transcrip-
tional regulation via recruiting and cooperating with many
different sequence-specific transcriptional factors to indirectly
anchor at gene promote regions,8 we deduce there must be
some other transcriptional factors co-anchoring at hTERT
promoter regions with NMI and contributing their supporting
and synergistic function in such reverse
transcriptional regulation. Based on IP and MS identification
and software prediction of possible hTERT promoter-binding
proteins, YY1 was focused and its involvement in
NMI-mediated transcriptional regulation of hTERT was
confirmed, as evidenced by the site mutation within its binding
sequence at hTERT promoter blocked NMI expression
change-mediated hTERT promoter activity change, and YY1
silencing consistently changed NMI knockdown-mediated
hTERT promoter activity enhancement. Hence, most likely,
NMI cooperates with YY1 to downregulate hTERT transcrip-
tion and expression and thereby inhibit the stemness and
growth of breast cancer cells. Besides YY1, some other
transcriptional factors may also contribute to such regulation.
What are these factors? How do they functionalize in
NMI-YY1-hTERT axis-mediated reduction of BCSCs stem-
ness? If it is irreplaceable, does it play positive or negative
regulatory effect? All these questions deserve better
investigation in our further study.
In summary, we found that NMI inhibited cancer stem cell
traits in breast cancer by downregulating hTERT signaling.We
also showed that NMI was lowly expressed in breast
cancer stem cell-enriched populations and the expression of
NMI was negatively correlated with hTERT in breast
cancer. The low NMI but high hTERT expression predicted
the worse status of clinical TNM stages in breast cancer
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patients. Further mechanistic insights demonstrated
that NMI functioned to regulate hTERT through its interaction
with YY1 in breast cancers. Based on the data from our
study, we propose a working model of NMI in the regulation of
BCSCs (Figure 8). Taken together, our results demon-
strated that NMI repressed breast cancer stem cell
traits by downregulating hTERT, and suggest that the
NMI-hTERT signaling axis might provide a novel therapeutic
target for the inhibition of breast cancer progression and
metastasis.
Materials and Methods
Cell culture and stable cell line selection. Human breast cancer MCF7
were grown in RPMI 1640 media supplemented with 10% FBS. T47D were grown in
RPMI 1640 media supplemented with 10% FBS and 0.2 units/ml insulin.
MDA-MB-231 was grown in DMEM media supplemented with 10% FBS. All cells
were grown in a 37 °C humidified incubator with 5% CO2. Stable silencing of NMI
expression was accomplished using short-hairpin RNA cloned into psi-LVRH1GP
vector (GeneCopoeia, Rockville, USA). The vector containing a non-targeting
shRNA was used as a control. NMI overexpression was accomplished by cloning
NMI cDNA into pEZ-Lv203 (GeneCopoeia), and the empty vector was used as a
control. The vectors were transfected using Lenti-Pac HIV Expression Packaging Kit
(GeneCopoeia, Cat: HPK-LvTR-20). The cells were selected in media
supplemented with 5 μg/ml of puromycin.
Mammosphere culture. Cells were cultured in DMEM/F-12 supplemented
with 2% B27, 20 ng/μl EGF and 10 ng/μl bFGF. Two thousand cells were seeded in
35 mm ultra-low attachment plate. After 2 weeks of culture, the spheres with
diameters larger than 50 μm were counted. When mammospheres were passaged,
sphere pellets were centrifuged and digested with trypsin-EDTA.
qRT-PCR. Total RNA was extracted using Trizol reagent (TaKaRa, Dalian, China)
and was transcribed into cDNA using the EasyScript One-Step gDNA Removal and
P
er
ce
n t
a g
e
of
sp
ec
im
e n
s
NMI low NMI high
N
M
I
hTERT
GSE8977
Stroma normal breast
P
er
ce
nt
ag
e
of
sp
ec
im
en
s
TNM
Normal Tumor
E
xp
re
ss
io
n
l e
ve
l
GSE70951
case 2
NMI hTERT
case 1
case 3
TNM
P
er
ce
nt
ag
e
of
sp
ec
i m
en
s
Figure 7 NMI inversely correlates with hTERT in breast cancer samples. (a) NMI mRNA expression level was detected using GEO database (GSE70951) from 43 pairs of
human breast normal and corresponding tumor tissue. (b) The expression level of NMI and hTERTwas detected using genome mRNA expression profiling data (GSE8977) from
GEO database. (c) The representative images for NMI and hTERT by IHC analysis in 138 human breast cancer specimens, (X 200). (d) Percentages of specimens with either low
or high NMI expression relative to hTERT level (P= 0.005). (e) The correlation of NMI with hTERT in breast cancer tissues was examined. Significance of correlation between
NMI and hTERTwas determined by using χ2 test. (f) NMI expression level was negatively correlated with the worse TNM stage (P= 0.034), and hTERT expression level was
positively correlated with the worse TNM stage (P= 0.001). (g) The relationship between the clinical characteristics and NMI/hTERT expression
hTERT CSCs traits
Nucleus
NMI
YY1
Cytoplasm
Figure 8 A schematic model of the role of NMI in regulating CSCs traits. NMI-
YY1 component binds to hTERT promoter to inhibit hTERT transcription, thereby
inhibiting cancer stem-like cell traits in breast cancer
NMI inhibits breast cancer stem cell traits
X Feng et al
9
Cell Death and Disease
cDNA Synthesis SuperMix (Transgen, Beijing, China, Cat: AE311). The expression
levels of the mRNAs were determined by qRT-PCR using SYBR Green (TaKaRa) in
an Mx3005 real-time PCR detection system. ATCB was used as an internal control.
All data represent the average of three repeated experiments. The primers used
were listed in Supplementary Table 1.
Flow cytometry. The identification of CD44+CD24-cells was performed using
APC mouse anti-human CD44 (BD Bioscience, CA, USA, Cat: 559942) and PE
mouse anti-human CD24 (BD Bioscience, Cat: 555428) antibodies. The APC
mouse IgG2b K Isotype control (BD Bioscience, Cat: 555745) and the PE mouse
IgG2a K Isotype control (BD Bioscience, Cat: 555574) were used as the isotype
controls. Cells were analyzed using an Accuri C6 Flow Cytometer.
Immunohistochemistry. Tissue microarray sides containing 138 breast
carcinomas were purchased from Shanghai Outdo Biotech (Shanghai, China). The
slides were heated at 65 °C for 30 min, followed by paraffin removal with xylene and
subsequent rehydration with ethanol. Antigen retrieval was performed in a chamber
containing citrate buffer (pH 6.0) for 20 min maintaining at a sub-boiling
temperature. Samples were blocked with 10% goat serum for 1 h each at room
temperature. 200 μl primary antibody was added to each slide and incubated
overnight at 4 °C (NMI monoclonal, Santa Cruz, Texas, USA, 1:100; hTERT
monoclonal, Santa Cruz, 1:100). The visualized signal was developed with 3,
3′-diaminobenzidine (DAB) and the slides were counterstained in hematoxylin. The
immunostaining analysis of NMI and hTERT protein expression was done based on
these tissue microarrays. For each tissue sample, protein expression was scored
according to the staining color: negative staining (no yellow); low staining (light
yellow); moderate or high staining (yellow brown or brown). With prior written
consent from patients, all the tissue samples had been obtained before anti-cancer
treatment.
Transwell invasion assay. Cell invasion ability was detected using 24-well
chemotaxis chambers (Corning, CA, USA, Cat: 3422). The cells were washed twice
with PBS, resuspended in 100 μl serum-free medium and added into the upper
chambers. The lower chambers were filled with 500 μl medium containing 20% fetal
bovine serum (FBS). The cells were incubated for 36/60 h in the upper chamber
coated with a mixture of serum-free medium and Matrigel (4:1; BD Biosciences,
Cat: 356234). The membrane were fixed in methyl alcohol for 10 min at room
temperature, stained with crystal violet for 10 min, washed 3 times with PBS and
dried off. The crystal violet was dissolved with 500 μl 33% acetic acid and the
OD570 value was measured.
Dual luciferase assays. The hTERT promoter (−902 to +40) was amplified
using normal human DNA as a template and cloned into the pGL4-Basic (Promega,
Beijing, China). MCF7 cells were seeded in 6-well plates. On the next day, the cells
were transfected with NMI sh-plasmids or control plasmid. At 24 h after transfection,
the cells were transfected with hTERT reporter plasmid and a pRL-TK internal
control. At 48 h after transfection, luciferase activity was measured using the dual
luciferase reporter assay system (Promega, Cat: E1910).
Co-immunoprecipitation assays. Nuclear protein lysates were first
incubated with anti-NMI antibody or mouse IgG overnight at 4 °C under rotation,
and then incubated with protein A/G plus-agarose beads (Santa Cruz
Biotechnology, Texas, USA, Cat: sc-2003) for 2 h. The precipitates were washed
with 500 μl PBS for three times, resuspended in 50 μl 2 × loading buffer, boiled at
95 °C for 10 min and subjected to western blot analysis.
Chromatin immunoprecipitation assays. The cells were fixed with 1%
formaldehyde for 10 min at 37 °C, then sonicated on ice to shear the DNA to 200 to
500 bp. One-third of the total cell lysate was used as the DNA input control. The
other two thirds of the lysate were subjected to immunoprecipitations with anti-YY1
and IgG antibody. The DNA was subjected to PCR to amplify a 121 bp region of the
hTERT promoter. The PCR products were resolved electrophoretic ally on a 2%
agarose gel and visualized by ethidium bromide staining. The primers used were
listed in Supplementary Table 2.
Immunofluorescence and confocal microscopy. The cells were
washed with PBS and were fixed with 4% paraformaldehyde (w/v) for 30 min and
permeabilized with 0.2% (w/v) Tritonx-100 in PBS for 5 min in dark. Then, the
samples were blocked with 10% BSA for 1 h, and incubated with the primary antibody
which were diluted in PBS containing 1% BSA overnight. After PBS washings, cells
were incubated for two hours with secondary antibody conjugated with Alexa Fluor
488 or Alexa Fluor 555. The nuclei were stained with Hoechst 33342.
Animal studies. All animal experiments were performed according to the
Dalian Medical University for the Care and Use of Laboratory Animals. Female Balb/
c nude mice at the age of 4 to 6 weeks were used in all studies. Starting from one
week before MCF7 cancer cell line injection, the mice were treated with
subcutaneous injection of estradiol cypionate (2 mg/kg in corn oil, MedChemEx-
press, Shanghai, China, Cat: HY-B1100) every week for 4 weeks in tumorigenesis
assays. The GFP-labeled MCF7 cells (3 × 106 in 100 μl PBS) were injected
subcutaneously into the left flank of each mouse. One group was injected with the
control shRNA GFP-labeled MCF7 stable cell line, the second group was injected
with the NMI knockdown GFP-labeled MCF7 stable cell line, the third group was
injected with the NMI knockdown/control vector GFP-labeled MCF7 stable cell line
and the fourth group was injected with the NMI knockdown/hTERT-knockdown
GFP-labeled MCF7 stable cell line. The tumor size was measured using Vernier
calipers once every three days from the twelfth day after injected and volumes were
calculated as following: V= (width2 × length)/2. At 21 day, the mice were narcotized
and the tumors were detected by Bioluminescence. Tissues of tumor were fixed in
10% formalin and embedded in paraffin for histologic analysis. GFP-labeled
MDA-MB-231 cells (1 × 106 cells in 100 μl PBS) were injected subcutaneously into
the left flank of each mouse. One group was injected with the control vector
GFP-labeled MDA-MB-231 stable cell line and the second group was injected with
the NMI overexpression GFP-labeled MDA-MB-231 stable cell line. To identify cell
metastasis ability, the GFP-labeled MDA-MB-231 stable cell lines were injected into
tail vein and the lung metastasis ability were detected by H&E staining and
bioluminescence using fluorescence microscope.
Statistical analyses. The data are presented as mean±S.D. in the figures. A
Student t-test was performed to compare the in vitro data. A log-rank test was
performed to compare tumor-free survival. P-values less than 0.05 were considered
statistically significant.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. This work was supported by the funds from the National
Natural Science Foundation of China (81322029, 81472178, 81372133, 31371512,
81470337); the State “973 Program” of China (2014CB542005); the Natural Science
Foundation of Liaoning Province (2014023009, 2015020661); the Education
Department of Liaoning Province in China (Scientific Research Projects,L2015142).
Author contributions
WD, WG, LK, WH and XF conceived the study, participated in the designing of the
study, interpreting data, drafted the manuscript and coordinating the study. XF, XiXu,
XiXi, KZ, WY, JW, RT, YG, JH, XZ and YL performed the experiments, analyzed and
prepared data for publication. XF, XiXu, XiXi, KZ and YC performed cell culture,
mammosphere culture, RT-PCR, western blotting, flow cytometry, immunohisto-
chemistry, animal experiments and statistical analyses. WY, JW and RT performed
dual luciferase assays and co-immunoprecipitation assays. YG, JH, XZ and YL
performed immunofluorescence and confocal microscopy and transwell invasion
assay. All authors read and approved the final manuscript.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA 2016; 66: 7–30.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al. Cancer statistics in
China, 2015. CA 2016; 66: 115–132.
3. Breast Cancer Treatment (PDQ(R)): Patient Version. PDQ Cancer Information Summaries.
2002.
4. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P et al. Breast cancer
cell lines contain functional cancer stem cells with metastatic capacity and a distinct
molecular signature. Cancer Res 2009; 69: 1302–1313.
5. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B et al. Aldehyde
dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in
inflammatory breast cancer. Clin Cancer Res 2010; 16: 45–55.
6. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M et al. Aldehyde dehydrogenase
activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is
predictive of metastasis. Stem Cells 2011; 29: 32–45.
NMI inhibits breast cancer stem cell traits
X Feng et al
10
Cell Death and Disease
7. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast
cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777–1785.
8. Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. Radiation-induced
reprogramming of breast cancer cells. Stem Cells 2012; 30: 833–844.
9. Li HZ, Yi TB, Wu ZY. Suspension culture combined with chemotherapeutic agents for sorting
of breast cancer stem cells. BMC Cancer 2008; 8: 135.
10. Bannasch D, Weis I, Schwab M. Nmi protein interacts with regions that differ between MycN
and Myc and is localized in the cytoplasm of neuroblastoma cells in contrast to
nuclear MycN. Oncogene 1999; 18: 6810–6817.
11. Schlierf B, Lang S, Kosian T, Werner T, Wegner M. The high-mobility group transcription factor
Sox10 interacts with the N-myc-interacting protein Nmi. J Mol Biol 2005; 353: 1033–1042.
12. Zhu M, John S, Berg M, Leonard WJ. Functional association of Nmi with Stat5 and Stat1 in
IL-2- and IFNgamma-mediated signaling. Cell 1999; 96: 121–130.
13. Hou J, Wang T, Xie Q, Deng W, Yang JY, Zhang SQ et al. N-Myc-interacting protein (NMI)
negatively regulates epithelial-mesenchymal transition by inhibiting the acetylation of
NF-kappaB/p65. Cancer Lett 2016; 376: 22–33.
14. Devine DJ, Rostas JW, Metge BJ, Das S, Mulekar MS, Tucker JA et al. Loss of N-Myc
interactor promotes epithelial-mesenchymal transition by activation of TGF-beta/SMAD
signaling. Oncogene 2014; 33: 2620–2628.
15. Fillmore RA, Mitra A, Xi Y, Ju J, Scammell J, Shevde LA et al. Nmi (N-Myc interactor) inhibits
Wnt/beta-catenin signaling and retards tumor growth. Int J Cancer 2009; 125: 556–564.
16. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize,
Tetrahymena and yeast to human cancer and aging. Nat Med 2006; 12: 1133–1138.
17. Ju Z, Rudolph KL. Telomeres and telomerase in cancer stem cells. Eur J Cancer 2006; 42:
1197–1203.
18. Kirkpatrick KL, Mokbel K. The significance of human telomerase reverse transcriptase
(hTERT) in cancer. Eur J Surg Oncol 2001; 27: 754–760.
19. Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT promoter
regulation for diagnosis and treatment of human cancers. Cancer Sci 2008; 99: 1528–1538.
20. Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G et al. hTERT-immortalized
prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and
carcinogenesis. Cancer Res 2006; 66: 3531–3540.
21. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H et al. Telomerase activation by
hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998; 18: 65–68.
22. Liu Z, Li Q, Li K, Chen L, Li W, Hou M et al. Telomerase reverse transcriptase promotes
epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 2013;
32: 4203–4213.
23. Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, Pattamatta P et al. The telomerase
inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
Cancer Res 2010; 70: 9494–9504.
24. Koziel JE, Herbert BS. The telomerase inhibitor imetelstat alone, and in combination with
trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast
cancer cells. Breast Cancer Res Treat 2015; 149: 607–618.
25. Moitra K. Overcoming multidrug resistance in cancer stem cells. BioMed Res Int 2015;
2015: 635745.
26. Sicchieri RD, da Silveira WA, Mandarano LR, de Oliveira TM, Carrara HH, Muglia VF et al.
ABCG2 is a potential marker of tumor-initiating cells in breast cancer. Tumour Biol 2015; 36:
9233–9243.
27. Xie ZY, Lv K, Xiong Y, Guo WH. ABCG2-meditated multidrug resistance and tumor-initiating
capacity of side population cells from colon cancer. Oncol Res Treat 2014; 37:
666–668 670-662.
28. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette
(ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3–29.
29. Li H, Lee TH, Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-
induced human telomerase reverse transcriptase gene (hTERT) promoter activity in
breast cancer. J Biol Chem 2002; 277: 20965–20973.
30. Shay JW, Wright WE. Telomeres and telomerase in normal and cancer stem cells. FEBS Lett
2010; 584: 3819–3825.
31. Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell 2013; 152:
390–393.
32. Armanios M, Greider CW. Telomerase and cancer stem cells. Cold Spring Harb Symp Quant
Biol 2005; 70: 205–208.
33. Sato R, Semba T, Saya H, Arima Y. Stem cells and epithelial-mesenchymal transition
(EMT) in cancer: biological implications and therapeutic targets. Stem Cells 2016; 34:
1997–2007.
34. Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells
and treatment resistance. Breast Cancer Res 2012; 14: 202.
35. Mathelier A, Fornes O, Arenillas DJ, Chen CY, Denay G, Lee J et al. JASPAR 2016: a major
expansion and update of the open-access database of transcription factor binding profiles.
Nucleic Acids Res 2016; 44: D110–D115.
36. Zaravinos A, Spandidos DA. Yin yang 1 expression in human tumors. Cell Cycle 2010; 9:
512–522.
37. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function,
and therapeutic implications in cancer biology. Oncogene 2006; 25: 1125–1142.
38. Deng Z, Wan M, Cao P, Rao A, Cramer SD, Sui G. Yin Yang 1 regulates the transcriptional
activity of androgen receptor. Oncogene 2009; 28: 3746–3757.
39. Wang ZT, Chen ZJ, Jiang GM, Wu YM, Liu T, Yi YM et al. Histone deacetylase inhibitors
suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast
cancer cells. Cell Signal 2016; 28: 506–515.
40. Sankar N, Baluchamy S, Kadeppagari RK, Singhal G, Weitzman S, Thimmapaya B. p300
provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc.
Oncogene 2008; 27: 5717–5728.
41. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells.
Nature 2001; 414: 105–111.
42. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;
411: 349–354.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from
the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2017
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
NMI inhibits breast cancer stem cell traits
X Feng et al
11
Cell Death and Disease
